High-Velocity Resistance Training for Brain Blood Flow and Cognitive Function in Older Adults

April 29, 2026 updated by: University of Illinois at Chicago

Training the Aging Brain Through Speed: Examining Cerebrovascular Adaptations Associated With Motor-Cognitive Performance Following High-Velocity Resistance Training in Older Adults at Risk for AD/ADRD

The goal of this clinical trial is to learn whether a 12-week high-velocity resistance training program can improve brain blood flow and thinking skills in adults ages 60 to 79 who are at higher risk for Alzheimer's disease and related dementias. Researchers want to understand whether this type of exercise can improve how well the brain regulates blood flow during mental and physical tasks and whether those changes are linked to improvements in thinking ability. The main questions this study aims to answer are whether high-velocity resistance training improves thinking skills such as executive function and processing speed, and whether it improves how blood flow in the brain responds during cognitive testing, changes in blood pressure, and controlled breathing tasks. Participants will complete two study visits at the University of Illinois Chicago, one before the program begins and one after 12 weeks. During these visits, researchers will measure strength, muscle power, and thinking skills. Participants will also complete non-invasive testing to measure blood flow in the brain using ultrasound. During some tasks, participants will walk on a treadmill at a comfortable pace while completing thinking tests. They will wear small sensors to measure heart rate, blood pressure, and breathing. After the first visit, participants will be randomly assigned, like flipping a coin, to one of two groups. One group will take part in supervised resistance training three times per week for 12 weeks at the University of Illinois Chicago. Each session will last about 60 minutes and will be supervised by trained exercise professionals. The other group will continue their usual daily activities for 12 weeks and then return for follow-up testing. Participants in the comparison group will be offered the exercise program after they complete the final study visit. Researchers hope this study will improve understanding of how structured exercise may support brain health in older adults at risk for dementia and help guide future prevention strategies.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is a single-site, randomized, parallel-group clinical trial designed to evaluate both behavioral efficacy and mechanistic target engagement of high-velocity resistance training (HVRT) in older adults at elevated risk for Alzheimer's disease and related dementias (AD/ADRD). The trial is structured as an early-stage efficacy study consistent with a Stage IIA framework, with emphasis on testing a hypothesized physiological mechanism linking exercise to cognitive outcomes. A growing body of research suggests that vascular dysfunction may contribute to cognitive decline and dementia risk. Altered cerebrovascular regulation, including impaired neurovascular coupling, reduced dynamic cerebral autoregulation, and diminished cerebrovascular reactivity to carbon dioxide, has been observed in older adults and in individuals with vascular risk factors. These physiological impairments may limit the brain's ability to appropriately regulate blood flow during cognitive and physical demands. Exercise interventions may improve vascular function; however, the specific effects of high-velocity resistance training on cerebrovascular regulatory mechanisms and their relationship to cognitive performance remain insufficiently characterized. High-velocity resistance training emphasizes rapid concentric muscle actions performed against moderate external loads. This training approach is designed to improve neuromuscular power, which declines with aging and is strongly associated with functional mobility. HVRT may provide distinct hemodynamic and neurovascular stimuli compared to traditional resistance training due to the speed of contraction and associated pressor responses. This study will test whether a 12-week supervised HVRT intervention produces measurable improvements in executive function, processing speed, and motor-cognitive performance, and whether such improvements are associated with changes in cerebrovascular regulation. Participants will be randomized in a 1:1 ratio to either the HVRT intervention or a waitlist control condition. The intervention consists of three supervised sessions per week for 12 weeks, using progressive loading phases spanning approximately 40 to 80 percent of one-repetition maximum. All training sessions are conducted in person under the supervision of trained exercise professionals following standardized operating procedures. The waitlist control group will maintain usual activities during the 12-week period and will be offered the exercise program after completing post-intervention testing. Cognitive and motor-cognitive performance will be assessed under both single-task (seated) and dual-task (treadmill walking) conditions to evaluate cognitive function under varying levels of physiological demand. Dual-task paradigms are included to probe real-world motor-cognitive integration and to assess whether exercise-related adaptations extend to functionally relevant conditions. Cerebrovascular regulation will be assessed non-invasively using transcranial Doppler ultrasound to measure cerebral artery blood flow velocity. Continuous electrocardiography, beat-to-beat blood pressure monitoring, and end-tidal carbon dioxide measurement will be recorded concurrently to permit integrated physiological modeling. Neurovascular coupling will be evaluated as the change in cerebral blood flow velocity during cognitive activation. Dynamic cerebral autoregulation will be assessed using oscillatory lower-body negative pressure protocols to induce controlled blood pressure fluctuations. Cerebrovascular reactivity will be assessed using a standardized hypercapnic rebreathing procedure to quantify the cerebral blood flow response to elevated carbon dioxide levels. Primary analyses will examine group-by-time interaction effects on cognitive performance. Secondary analyses will evaluate changes in neurovascular coupling, dynamic cerebral autoregulation, and cerebrovascular reactivity. Exploratory analyses will estimate whether changes in cerebrovascular regulation statistically mediate intervention-related improvements in cognitive outcomes and whether biological sex moderates these associations. These mechanistic analyses are intended to inform the design of future fully powered efficacy trials. This study will contribute to understanding whether a scalable, supervised resistance training intervention can engage cerebrovascular mechanisms linked to cognitive performance in older adults at elevated dementia risk. Findings may inform the development of targeted exercise-based strategies to support brain health in aging populations.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Stacey E Aaron, PhD
  • Phone Number: 312-355-7220
  • Email: seaaron@uic.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 60 to 79 years
  • Able to walk on a treadmill at a comfortable, self-selected pace for at least 30 minutes with short breaks
  • Has at least one vascular risk factor (such as high blood pressure or high cholesterol)
  • Has a first-degree family history of dementia or self-reported concerns about memory or thinking
  • Fluent in English
  • Willing and able to provide written informed consent
  • Cleared to participate in supervised resistance training based on physical activity screening and, if required, physician clearance

Exclusion Criteria:

  • Diagnosis of Alzheimer disease, other dementia, stroke, Parkinson disease, multiple sclerosis, or another major neurological disorder
  • Unstable cardiovascular disease (such as recent heart attack, unstable chest pain, or uncontrolled abnormal heart rhythm)
  • Uncontrolled high blood pressure
  • Major psychiatric illness that would interfere with participation
  • Medical condition that makes moderate-to-high intensity resistance training unsafe
  • Current participation in structured high-intensity resistance training
  • Any medical condition that, in the opinion of the study investigator, would increase risk during participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: High-Velocity Resistance Training
Participants in this arm will complete a 12-week supervised high-velocity resistance training program. Sessions will occur three times per week and last approximately 60 minutes each. Exercises will include multi-joint upper- and lower-body movements performed at moderate loads, progressing from approximately 40 to 80 percent of one-repetition maximum over three phases. All sessions will be conducted in person and supervised by trained exercise professionals. Participants will also complete baseline and post-intervention cognitive and cerebrovascular assessments.
Behavioral: High-Velocity Resistance Training
This intervention consists of supervised resistance training emphasizing rapid concentric muscle contractions performed against moderate external loads. Participants will train three times per week for 12 weeks, with each session lasting approximately 60 minutes. The program includes progressive loading across three phases, beginning at approximately 40 to 50 percent of one-repetition maximum, progressing to 50 to 65 percent, and then to 65 to 80 percent. Exercises target major upper- and lower-body muscle groups using resistance equipment. All sessions are conducted in person under supervision of trained exercise professionals to ensure proper technique, safety monitoring, and progression.
Other Names:
  • Resistance Training
  • Power Training
No Intervention: Waitlist Control (Usual Activity)
Participants in this arm will maintain their usual daily activities for 12 weeks and will not receive structured exercise during the study period. They will complete the same baseline and post-intervention cognitive and cerebrovascular assessments as the intervention group. After completing post-intervention testing, participants will be offered the supervised resistance training program.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Executive Function Standard Score
Time Frame: Baseline and 12 weeks
Executive function will be assessed using standardized computerized cognitive tests from the National Institutes of Health Toolbox. Participants will first complete the tests in a seated single-task condition, followed by completion of the same tests during treadmill walking (dual-task condition). Age-adjusted standard scores will be used (mean = 100, standard deviation = 15; higher scores indicate better performance). Dual-task cost will be calculated as the percent difference between dual-task and seated performance using the formula: [(dual-task standard score - single-task standard score) / single-task standard score] × 100. The primary metric is the change in executive function dual-task cost (%) from baseline to 12 weeks.
Baseline and 12 weeks
Change in Processing Speed Standard Score
Time Frame: Baseline and 12 weeks
Processing speed will be assessed using standardized computerized cognitive tests from the National Institutes of Health Toolbox. Participants will first complete the tests in a seated single-task condition, followed by completion of the same tests during treadmill walking (dual-task condition). Age-adjusted standard scores will be used (mean = 100, standard deviation = 15; higher scores indicate better performance). Dual-task cost will be calculated as the percent difference between dual-task and seated performance using the formula: [(dual-task standard score - single-task standard score) / single-task standard score] × 100. The primary metric is the change in processing speed dual-task cost (%) from baseline to 12 weeks.
Baseline and 12 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Neurovascular Coupling
Time Frame: Baseline and 12 weeks
Neurovascular coupling will be assessed using transcranial Doppler ultrasound to measure cerebral artery blood flow velocity (cm/s). Neurovascular coupling is defined as the change in cerebral blood flow velocity during cognitive activation compared to resting baseline. The primary metric will be the task-related change in cerebral blood flow velocity expressed as absolute change (cm/s) and/or percent change (%). Greater task-related increases indicate improved neurovascular responsiveness.
Baseline and 12 weeks
Change in Dynamic Cerebral Autoregulation
Time Frame: Baseline and 12 weeks
Dynamic cerebral autoregulation will be assessed using transcranial Doppler ultrasound during controlled oscillatory lower-body negative pressure. Projection pursuit regression analysis will be applied to characterize the nonlinear relationship between arterial blood pressure and cerebral blood flow velocity. The primary autoregulatory metrics will include the active autoregulatory range (mmHg), defined as the arterial pressure range over which cerebral blood flow velocity remains relatively stable, as well as the slope of the active autoregulatory range, the rising slope, and the falling slope (all expressed in cm/s/mmHg). A wider active autoregulatory range and flatter slopes indicate more effective autoregulatory buffering capacity.
Baseline and 12 weeks
Change in Cerebrovascular Reactivity
Time Frame: Baseline and 12 weeks
Cerebrovascular reactivity will be assessed using transcranial Doppler ultrasound during a standardized carbon dioxide rebreathing protocol. Reactivity will be quantified as the slope of the cerebral blood flow velocity response to changes in end-tidal carbon dioxide. The primary metric will be expressed as cm/s/mmHg or percent change per mmHg. Steeper slopes indicate improved cerebrovascular responsiveness.
Baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Illinois at Chicago

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute on Aging (NIA)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 23, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 3, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 5, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 29, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2026-0214
  • 5P30AG022849-22 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on At Risk for Cognitive Decline

Clinical Trials on High-Velocity Resistance Training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings